{"disease":{"id":"bipolar-disorder-depression","name":"bipolar disorder depression"},"drugs":{"marketed":[{"drug_id":"fluoxetine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prozac","generic_name":"fluoxetine","company_name":"Eli Lilly and Company","drug_phase":"marketed","molecular_target":"Serotonin reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":81,"revenue":"1000.0","mechanism":"Fluoxetine inhibits CNS neuronal uptake of serotonin, though exact mechanism unknown."},{"drug_id":"olanzapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zyprexa","generic_name":"olanzapine","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"Atypical Antipsychotic [EPC]","quality_score":38,"revenue":"300","mechanism":null},{"drug_id":"lurasidone","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Latuda","generic_name":"LURASIDONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Atypical Antipsychotic","quality_score":80,"revenue":null,"mechanism":"Latuda works by blocking the action of serotonin at the 5-hydroxytryptamine receptor 2A, which helps to regulate mood and reduce symptoms of psychosis."},{"drug_id":"doxepin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"seroquel","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Seroquel","company_name":"University of Pittsburgh","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapin","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Quetiapin","company_name":"Sykehuset Innlandet HF","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"quetiapine","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Seroquel","generic_name":"quetiapine","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"zyprexa","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zyprexa","company_name":"Washington University School of Medicine","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prozac","indication_name":"Bipolar affective disorder, current episode depression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prozac","company_name":"RenJi Hospital","drug_phase":"marketed","molecular_target":"Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":30,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03598868","title":"Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07246044","title":"HD-tDCS for Adolescent Bipolar Depression Targeting S1","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jiangsu Province Nanjing Brain Hospital","has_results":false},{"nct_id":"NCT06661616","title":"Cognitive Effects Associated With Hippocampal Neurogenesis Induced by ECT in the Treatment of Depression","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Centre Hospitalier St Anne","has_results":false},{"nct_id":"NCT04211961","title":"Scopolamine in Bipolar Depression","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Dr. Brian Hallahan","has_results":true},{"nct_id":"NCT07510646","title":"Transcranial Photobiomodulation for Bipolar Depression","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Vielight Inc.","has_results":false},{"nct_id":"NCT07211217","title":"Time Restricted Eating (TRE) in Bipolar Disorder","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06869187","title":"Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Autobahn Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04430959","title":"Candesartan as an Adjunctive Treatment for Bipolar Depression","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}